@article{63c1d26f4cd84447b006b2783e21c545,
title = "Immunologically relevant effects of radiation therapy on the tumor microenvironment",
abstract = "Focal radiation therapy (RT) has been successfully employed to clinically manage multiple types of cancer for more than a century. Besides being preferentially cytotoxic for malignant cells over their nontransformed counterparts, RT elicits numerous microenvironmental alterations that appear to factor into its therapeutic efficacy. Here, we briefly discuss immunostimulatory and immunosuppressive microenvironmental changes elicited by RT and their impact on tumor recognition by the host immune system.",
keywords = "CGAS, ICD, mtDNA, TGFβ, TREG cells, type I IFN",
author = "Claudia Galassi and Vanessa Klapp and Formenti, {Silvia C.} and Sandra Demaria and Lorenzo Galluzzi",
note = "Acknowledgements: CG is supported by a fellowship from the American Italian Cancer Foundation (AICF; #223565–01). VK is supported by a grant from the Luxembourg National Research Fund (FNR) (PRIDE19/14254520/i2TRON). SCF is supported by a U54 grant from NIH/NCI (#CA274291), by a Transformative Breast Cancer Consortium Grant from the US DoD BCRP (#W81XWH2120034) by a Breakthrough Level 3 grant from the US DoD BCRP (#W81XWH1910141), by a Breakthrough Level 2 grant from the US DoD BCRP (#W81XWH-1910101) and by a grant from the Breast Cancer Research Foundation (BCRF-22-053). SD is supported by an R01 grant from NIH/NCI (#R01CA201246), a grant from the STARR Cancer Consortium (#I14–0043), by a Breakthrough Level 3 grant from the US DoD BCRP (#W81XWH1910142), by a grant from the BCRF, and by funding from Boehringer Ingelheim (#BIP578201). LG is/has been supported (as a PI unless otherwise indicated) by two Breakthrough Level 2 grants from the US DoD BCRP (#BC180476P1; #BC210945), by a grant from the STARR Cancer Consortium (#I16–0064), by a Transformative Breast Cancer Consortium Grant from the US DoD BCRP (#W81XWH2120034, PI: Formenti), by a U54 grant from NIH/NCI (#CA274291, PI: Deasy, Formenti, Weichselbaum), by the 2019 Laura Ziskin Prize in Translational Research (#ZP-6177, PI: Formenti) from the Stand Up to Cancer (SU2C), by a Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang) grant from the Leukemia and Lymphoma Society (LLS), by a Rapid Response Grant from the Functional Genomics Initiative (New York, US), by startup funds from the Dept. of Radiation Oncology at Weill Cornell Medicine (New York, US), by industrial collaborations with Lytix Biopharma (Oslo, Norway), Promontory (New York, US) and Onxeo (Paris, France), as well as by donations from Promontory (New York, US), the Luke Heller TECPR2 Foundation (Boston, US), Sotio a.s. (Prague, Czech Republic), Lytix Biopharma (Oslo, Norway), Onxeo (Paris, France), Ricerchiamo (Brescia, Italy), and Noxopharm (Chatswood, Australia). Publisher Copyright: {\textcopyright} 2023 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.",
year = "2023",
month = sep,
day = "28",
doi = "10.1042/EBC20220248",
language = "English",
volume = "67",
pages = "979--989",
journal = "Essays in Biochemistry",
issn = "0071-1365",
publisher = "Portland Press, Ltd.",
number = "6",
}